| Autor: |
Li, Zhu, Roger J, Brüggemann, Jonathan, Uy, Angela, Colbers, Matthew W, Hruska, Ellen, Chung, Karen, Sims, Blisse, Vakkalagadda, Xiaohui, Xu, Ron H N, van Schaik, David M, Burger, Richard J, Bertz |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Journal of clinical pharmacology. 57(2) |
| ISSN: |
1552-4604 |
| Popis: |
Voriconazole, a broad-spectrum triazole antifungal agent, is metabolized by cytochrome P450 (CYP) 2C19 and, to a lesser extent, by CYP3A. Genetic polymorphism of CYP2C19 not only plays a prominent role in its disposition but may also influence potential drug interactions with CYP450 modulators such as ritonavir. This study assessed 2-way drug interactions of voriconazole added on to ritonavir-boosted atazanavir in both CYP2C19 extensive-metabolizer (EM) and poor-metabolizer (PM) healthy subjects. Each subject received voriconazole alone on days 1-3, followed by a 7-day washout. Atazanavir/ritonavir 300/100 mg once daily was given on days 11-30 and voriconazole on days 21-30. Voriconazole doses were 200 mg (400 mg on days 1 and 21) twice daily and 50 mg (100 mg on days 1 and 21) twice daily for CYP2C19 EM and PM subjects, respectively. On coadministration, voriconazole AUC and C |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text